Nasdaq

Can-Fite BioPharma Initiates Phase II Clinical Study for Piclidenoson in Patients with Lowe Syndrome

Can-Fite BioPharma Ltd. has announced the completion of a Phase II study design and is preparing to initiate a clinical study for Piclidenoson, a novel treatment for Lowe Syndrome, a rare genetic ...
Seeking Alpha

Can-Fite to Initiate Phase II Study in the Rare Genetic Disease Lowe Syndrome with Piclidenoson

FDA & EMA approvals for rare genetic diseases are fast and require clinical studies with small number of patients Ramat Gan, Israel, March 19, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (CANF), ...
Overdrive

Owner-op-founded Alabama truck show and foundation for Lowe Syndrome kick off

Truck shows start up for a variety of reasons, some simply for fun and fellowship among the trucking community, others to raise money for a specific charity, and much more in between. The Show for ...
Nasdaq

Can-Fite to Initiate Phase II Study in the Rare Genetic Disease Lowe Syndrome with Piclidenoson

Ramat Gan, Israel, March 19, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that ...